Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Nova Mentis Life Science Corp (NOVA.CN)

Nova Mentis Life Science Corp (NOVA.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 742
  • Shares Outstanding, K 148,319
  • Annual Sales, $ 0 K
  • Annual Income, $ -2,466 K
  • 60-Month Beta -1.74
  • Price/Sales 25.70
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade NOVA.CN with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.02
  • Most Recent Earnings $0.00 on 08/26/24
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    SIC-2834 Pharmaceutical Preparations

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0050 unch
on 09/18/24
0.0150 -66.67%
on 08/22/24
-0.0050 (-50.00%)
since 08/16/24
3-Month
0.0050 unch
on 09/18/24
0.0200 -75.00%
on 07/16/24
-0.0050 (-50.00%)
since 06/18/24
52-Week
0.0050 unch
on 09/18/24
0.0300 -83.33%
on 11/20/23
-0.0200 (-80.00%)
since 09/18/23

Most Recent Stories

More News
Nova Mentis Assigns Intellectual Property

Vancouver, British Columbia--(Newsfile Corp. - August 27, 2024) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company") is pleased to announce it has entered into...

NMLSF : 0.0050 (-29.58%)
LUDG : 0.1825 (-7.59%)
NOVA.CN : 0.0050 (unch)
Nova Mentis Announces Change of Directors

Vancouver, British Columbia--(Newsfile Corp. - February 26, 2024) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company") announces the appointment of Steve Loutskou...

NMLSF : 0.0050 (-29.58%)
NOVA.CN : 0.0050 (unch)
Nova Mentis Applauds Government Decision to Create Rare Disease Advisory Group

Vancouver, British Columbia--(Newsfile Corp. - November 3, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader...

NMLSF : 0.0050 (-29.58%)
NOVA.CN : 0.0050 (unch)
Nova Mentis Announces Participant Screening Underway in Canada's First Psilocybin Clinical Trial for Fragile X Syndrome

Vancouver, British Columbia--(Newsfile Corp. - August 30, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader...

NMLSF : 0.0050 (-29.58%)
NOVA.CN : 0.0050 (unch)
Nova Mentis to Enter mRNA AI Diagnostics Business

Vancouver, British Columbia--(Newsfile Corp. - April 26, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader...

NMLSF : 0.0050 (-29.58%)
NOVA.CN : 0.0050 (unch)
Nova Mentis Begins Recruitment in First-of-its-Kind Health Canada Psilocybin Trial

Vancouver, British Columbia--(Newsfile Corp. - April 18, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader...

NMLSF : 0.0050 (-29.58%)
NOVA.CN : 0.0050 (unch)
Nova Mentis Receives Institutional Review Board Approval to Commence Psilocybin Clinical Trial

Vancouver, British Columbia--(Newsfile Corp. - April 11, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader...

NMLSF : 0.0050 (-29.58%)
NOVA.CN : 0.0050 (unch)
Nova Mentis Provides Corporate Update and 2023 Outlook

Vancouver, British Columbia--(Newsfile Corp. - April 5, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader...

NMLSF : 0.0050 (-29.58%)
NOVA.CN : 0.0050 (unch)
Novel Therapeutic Solutions are Needed as Autism Rates Increase

Vancouver, British Columbia--(Newsfile Corp. - March 29, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader...

NMLSF : 0.0050 (-29.58%)
NOVA.CN : 0.0050 (unch)
Nova Mentis Granted Health Canada Section 56 Exemption to Begin Psilocybin Clinical Trial

Vancouver, British Columbia--(Newsfile Corp. - February 14, 2023) - Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) ("NOVA" or the "Company"), a biotechnology company and global leader...

NMLSF : 0.0050 (-29.58%)
NOVA.CN : 0.0050 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Nova Mentis Life Science Corp is a Canadian-based biotechnology company. It is engaged in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova uses psilocybin in the treatment of Fragile X Syndrome (FXS). The company's goal is to diagnose and treat debilitating...

See More

Key Turning Points

3rd Resistance Point 0.0050
2nd Resistance Point 0.0050
1st Resistance Point 0.0050
Last Price 0.0050
1st Support Level 0.0050
2nd Support Level 0.0050
3rd Support Level 0.0050

See More

52-Week High 0.0300
Fibonacci 61.8% 0.0204
Fibonacci 50% 0.0175
Fibonacci 38.2% 0.0145
Last Price 0.0050
52-Week Low 0.0050

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar